7uw7
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==Crystal structure of the Human TRIP12 WWE domain (isoform 2) in complex with ADP== | ==Crystal structure of the Human TRIP12 WWE domain (isoform 2) in complex with ADP== | ||
- | <StructureSection load='7uw7' size='340' side='right'caption='[[7uw7]]' scene=''> | + | <StructureSection load='7uw7' size='340' side='right'caption='[[7uw7]], [[Resolution|resolution]] 1.17Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7UW7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7UW7 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[7uw7]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7UW7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7UW7 FirstGlance]. <br> |
- | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7uw7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7uw7 OCA], [https://pdbe.org/7uw7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7uw7 RCSB], [https://www.ebi.ac.uk/pdbsum/7uw7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7uw7 ProSAT]</span></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.17Å</td></tr> |
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ADP:ADENOSINE-5-DIPHOSPHATE'>ADP</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7uw7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7uw7 OCA], [https://pdbe.org/7uw7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7uw7 RCSB], [https://www.ebi.ac.uk/pdbsum/7uw7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7uw7 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
+ | == Disease == | ||
+ | [https://www.uniprot.org/uniprot/TRIPC_HUMAN TRIPC_HUMAN] Non-specific syndromic intellectual disability. The disease is caused by variants affecting the gene represented in this entry. | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/TRIPC_HUMAN TRIPC_HUMAN] E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair (PubMed:19028681, PubMed:22884692). Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins (PubMed:19028681). Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes (PubMed:22884692). In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress (PubMed:20208519). In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation (PubMed:20208519). Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A (PubMed:20208519). Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation (PubMed:18627766). Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins (PubMed:20829358). Mediates ubiquitination of ASXL1: following binding to N(6)-methyladenosine methylated DNA, ASXL1 is ubiquitinated by TRIP12, leading to its degradation and subsequent inactivation of the PR-DUB complex (PubMed:30982744).<ref>PMID:18627766</ref> <ref>PMID:19028681</ref> <ref>PMID:20208519</ref> <ref>PMID:20829358</ref> <ref>PMID:22884692</ref> <ref>PMID:30982744</ref> | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
+ | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Arrowsmith CH]] | [[Category: Arrowsmith CH]] |
Current revision
Crystal structure of the Human TRIP12 WWE domain (isoform 2) in complex with ADP
|
Categories: Homo sapiens | Large Structures | Arrowsmith CH | Dong A | Edwards AM | Halabelian L | Kimani S | Li Y